Linezolid Fresenius Kabi

Linezolid, the active ingredient in Linezolid Fresenius Kabi, is an oxazolidinone presented as an injectable solution for intravenous use. It treats complicated skin and skin structure infections, community‑acquired bacterial pneumonia, nosocomial pneumonia and methicillin‑resistant Staphylococcus aureus (MRSA) infections in adult patients.

GNH USA supplies Linezolid Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company follows strict quality standards and provides regulatory documentation to support import and clinical use. Customers receive reliable delivery and technical support for product handling.

Linezolid is indicated for bacterial infections that are resistant to other antibiotics, particularly those involving the skin, lungs, and methicillin‑resistant Staphylococcus aureus.

Complicated skin and skin structure infections: effective against Gram‑positive pathogens, including MRSA, reducing infection severity. Community‑acquired bacterial pneumonia: improves clinical outcomes in adult patients with susceptible organisms. Nosocomial pneumonia: provides coverage for hospital‑acquired Gram‑positive infections, including MRSA.

Linezolid may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Headache - Rash

Serious or Rare Side Effects: - Thrombocytopenia - Peripheral neuropathy - Serotonin syndrome (especially with serotonergic agents) - Optic neuritis

Use of Linezolid requires careful clinical assessment and monitoring. - Renal impairment: assess renal function and adjust therapy as needed. - Hepatic dysfunction: monitor liver enzymes during prolonged treatment. - Concomitant serotonergic drugs: avoid or use with caution due to risk of serotonin syndrome. - Hematologic monitoring: perform regular complete blood counts to detect thrombocytopenia or anemia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin syndrome. - Rifampin: reduces linezolid plasma concentrations, compromising efficacy. - Tyramine‑containing foods and drugs: may cause hypertensive reactions when combined with linezolid’s MAO activity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Anticonvulsants (e.g., carbamazepine): may lower linezolid levels. - Ethanol: may increase risk of hypotension; observe patient.